A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.
Early attempts to improve BCG have focused on increasing the expression of prominent antigens and adding recombinant toxins or cytokines to influence antigen presentation. One such modified BCG vaccine candidate has been withdrawn from human clinical trials due to adverse effects. BCG was derived from virulent Mycobacterium bovis and retains much of its capacity for suppressing host immune responses. Accordingly, we have used a different strategy for improving BCG based on reducing its immune suppressive capacity. We made four modifications to BCG Tice to produce 4dBCG and compared it to the parent vaccine in C57Bl/6 mice. The modifications included elimination of the oxidative stress sigma factor SigH, elimination of the SecA2 secretion channel, and reductions in the activity of iron co-factored superoxide dismutase and glutamine synthetase. After IV inoculation of 4dBCG, 95% of vaccine bacilli were eradicated from the spleens of mice within 60 days whereas the titer of BCG Tice was not significantly reduced. Subcutaneous vaccination with 4dBCG produced greater protection than vaccination with BCG against dissemination of an aerosolized challenge of M. tuberculosis to the spleen at 8 weeks post-challenge. At this time, 4dBCG-vaccinated mice also exhibited altered lung histopathology compared to BCG-vaccinated mice and control mice with less well-developed lymphohistiocytic nodules in the lung parenchyma. At 26 weeks post-challenge, 4dBCG-vaccinated mice but not BCG-vaccinated mice had significantly fewer challenge bacilli in the lungs than control mice. In conclusion, despite reduced persistence in mice a modified BCG vaccine with diminished antioxidants and glutamine synthetase is superior to the parent vaccine in conferring protection against M. tuberculosis. The targeting of multiple immune suppressive factors produced by BCG is a promising strategy for simultaneously improving vaccine safety and effectiveness.
Veterans Affairs Medical Center, Syracuse, NY 13212, USA. shoenc@cnyrc.org.
Carolyn M
CM
Shoen
Veterans Affairs Medical Center, Syracuse, NY 13212, USA. Michelle.Destefano@va.gov.
Michelle S
MS
DeStefano
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. cindy.hager@vanderbilt.edu.
Cynthia C
CC
Hager
Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. kyitoe@catham.org.|Veterans Affairs Medical Center, Nashville, TN 37212, USA. kyitoe@catham.org.
Kyi-Toe
KT
Tham
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA. braunste@med.unc.edu.
Miriam
M
Braunstein
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Alexandria.Allen@mlh.org.
Alexandria D
AD
Allen
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. hirham@bellsouth.net.
Hiriam O
HO
Gates
Veterans Affairs Medical Center, Syracuse, NY 13212, USA. Michael.Cynamon@va.gov.
Michael H
MH
Cynamon
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. doug.kernodle@vanderbilt.edu.|Veterans Affairs Medical Center, Nashville, TN 37212, USA. doug.kernodle@vanderbilt.edu.|Department of Microbiology, Immunology and Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. doug.kernodle@vanderbilt.edu.
Douglas S
DS
Kernodle
Bacillus Calmette-Guérin (BCG); antioxidants; glutamine synthetase; immune suppression; immunity; sigma factor; superoxide dismutase; tuberculosis; vaccine